Drugs / AVI-4126
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00343148 | Jun 2006 | neoplasm | Sarepta Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2011-05-06 | Sarepta Therapeutics, Inc. | Results Data From AVI BioPharma's RNA-Based Hemorrhagic Fever and Infectious Disease Programs to Be Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases sarepta.com ↗
The presentation, which will be given during the session called "New Antimicrobials: Preclinical and Clinical Studies," will feature data demonstrating the ability of multiple PMOs, AVI-4020, AVI-4126 and AVI-4065, to cross the blood-brain barrier of normal healthy volunteers. |
| 2007-10-25 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference sarepta.com ↗
Furthermore, the six-month IVUS showed promising results on AVI-4126 efficacy in preventing restenosis, which is comparable to DES results at our institution, |
| 2006-11-10 | Sarepta Therapeutics, Inc. | Results AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System sarepta.com ↗
AVI BioPharma, Inc. (Nasdaq:AVII), today announced human clinical trial results showing that three distinct NEUGENE(R) antisense drugs entered the cerebral spinal fluid (CSF) of healthy adult male volunteers following a single 100 mg dose via intravenous (IV) or subcutaneous (subq) injections. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-05-06 | Sarepta Therapeutics, Inc. | Data From AVI BioPharma's RNA-Based Hemorrhagic Fever and Infectious Disease Programs to Be Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases sarepta.com ↗ |
| 2007-10-25 | Sarepta Therapeutics, Inc. | AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference sarepta.com ↗ |
| 2006-11-10 | Sarepta Therapeutics, Inc. | AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System sarepta.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVI-4126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00343148 ↗ |
| Known as | RESTEN-NG | “AVI-4126 Injection (RESTEN-NG®)” NCT00343148 ↗ |
| Route | Intravenous | “Following Intravenous Administration” NCT00343148 ↗ |